Hindi nagbibigay ng serbisyo ang XM sa mga residente ng Estados Unidos.

Hindi nagbibigay ng serbisyo ang XM sa mga residente ng Estados Unidos.
W
W

Walgreens

Balita

Reuters - 2 araw ang nakaraan

U.S. Autodesk, Elastic NV, GMS

U.S. RESEARCH ROUNDUP-Autodesk, Elastic NV, GMS Aug 30 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Autodesk, Elastic NV and GMS, on Friday. HIGHLIGHTS * Autodesk Inc ADSK.O : RBC raises target price to $313 from $290 * Elastic NV ESTC.N : Piper Sandler cuts target price to $100 from $131 * GMS Inc GMS.N : Truist Securities cuts target price to $90 from $95 * Nvidia Corp NVDA.O : Baird raises target price to $150 f
A
G
M
N
N
W
C
D
U
D
S
Reuters - 4 araw ang nakaraan

U.S. STOCKS Lumen Technologies, Insulet, PDD Holdings

BUZZ-U.S. STOCKS ON THE MOVE-Lumen Technologies, Insulet, PDD Holdings Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The S&P 500 rose on Tuesday in mixed trading ahead of a highly anticipated quarterly report from Nvidia and economic data expected later in the week.
N
W
U
U
C
M
R
Reuters - 1 linggo ang nakaraan

Evolent Health in sale talks after receiving takeover interest, sources say

CORRECTED-EXCLUSIVE-Evolent Health in sale talks after receiving takeover interest, sources say Corrects Aug 22 story to show that Elevance Health dropped out of the bidding process for Evolent at an earlier stage By Milana Vinn and Anirban Sen NEW YORK, Aug 22 (Reuters) - Evolent Health EVH.N is in talks with private equity firms and healthcare services providers for a potential sale, in a process that kicked off after it received takeover interest, people familiar with the matter said on Thurs
W
Reuters - 2 linggo ang nakaraan

Tylenol ADHD lawsuits cannot go forward, judge rules

Tylenol ADHD lawsuits cannot go forward, judge rules By Brendan Pierson Aug 20 (Reuters) - Plaintiffs claiming that Kenvue's KVUE.N popular painkiller Tylenol causes attention deficit hyperactivity disorder (ADHD) in the children of mothers who took it while pregnant have lost a last ditch bid to revive their claims after a judge rejected their last remaining expert witness.
W
Reuters - 2 linggo ang nakaraan

Walgreens and BARDA Form Strategic Partnership

BRIEF-Walgreens and BARDA Form Strategic Partnership Aug 19 (Reuters) - Walgreens Boots Alliance Inc WBA.O : WALGREENS AND BARDA FORM STRATEGIC PARTNERSHIP TO STRENGTHEN DECENTRALIZED CLINICAL TRIALS MODEL AND REPORTING WALGREENS BOOTS ALLIANCE INC - PARTNERS WITH BARDA ON PHASE IV COVID-19 TRIAL Source text for Eikon: ID:nBw4k7VFCa Further company
W
Reuters - 2 linggo ang nakaraan

Harris' anti-price gouging plan could build on US state law

EXPLAINER-Harris' anti-price gouging plan could build on US state law By Jody Godoy Aug 16 (Reuters) - As Vice President Kamala Harris focuses on price gouging in her presidential campaign, state laws and laws proposed by her colleagues in the Senate show potential paths for a crackdown on high prices. The Democratic candidate planned to lay out her anti-price gouging and other economic proposals in a speech in Raleigh, North Carolina, on Friday.
A
K
W
Reuters - 3 linggo ang nakaraan

Walgreens Boots Alliance Announces Pricing Of $750,000,000 Of Senior Unsecured Notes

BRIEF-Walgreens Boots Alliance Announces Pricing Of $750,000,000 Of Senior Unsecured Notes Aug 8 (Reuters) - Walgreens Boots Alliance Inc WBA.O : WALGREENS BOOTS ALLIANCE ANNOUNCES PRICING OF $750,000,000 OF SENIOR UNSECURED NOTES Source text for Eikon: ID:nBw9lKL4Ya Further company coverage: WBA.O
W
Reuters - 3 linggo ang nakaraan

Walgreens explores options for VillageMD business

UPDATE 1-Walgreens explores options for VillageMD business Adds details and background throughout Aug 7 (Reuters) - Walgreens Boots Alliance WBA.O said on Wednesday it was exploring options for VillageMD, including a sale, citing the primary-care provider's substantial cash needs. VillageMD, a core part of Walgreens' push to expand beyond its legacy pharmacy operations, has planned to close a substantial number of poorly performing clinics to cut costs.
W
Reuters - 3 linggo ang nakaraan

Walgreens Currently Evaluating A Variety Of Options With Respect To Village MD

BRIEF-Walgreens Currently Evaluating A Variety Of Options With Respect To Village MD Aug 7 (Reuters) - Walgreens Boots Alliance Inc WBA.O : WALGREENS: CURRENTLY EVALUATING A VARIETY OF OPTIONS WITH RESPECT TO VILLAGEMD WALGREENS: CO AND VILLAGEMD ACKNOWLEDGED EXISTENCE OF DEFAULTS UNDER VILLAGEMD SECURED LOAN - SEC FILING WALGREENS: CO AND VILLAGEM
W
Reuters - 3 linggo ang nakaraan

Walgreens explores options for VillageMD business

CORRECTED-Walgreens explores options for VillageMD business Corrects to say Walgreens is exploring options, including a sale, for VillageMD business, not just exploring a sale Aug 7 (Reuters) - Walgreens Boots Alliance WBA.O said on Wednesday it was exploring options, including a sale, for its VillageMD business. Reporting by Christy Santhosh; Edit
W
Reuters - 4 linggo ang nakaraan

S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT

BUZZ - S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT S&P 500 .SPX Top Performers Percent Change Kellanova K.N +15.2% Tyson Foods Inc TSN.N +2.3% Advanced Micro Devices Inc AMD.OQ +2.1% Constellation Energy Corp CEG.OQ +2.0% AMETEK Inc AME.N +1.8% Bottom Performers Percent Change Intel Corp INTC.OQ -7.3% NVIDIA Corp NVDA.OQ -6.7%
I
K
N
W
A
U
A
Reuters - 4 linggo ang nakaraan

S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT

BUZZ - S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT S&P 500 .SPX Top Performers Percent Change Kellanova K.N +13.5% ON Semiconductor Corp ON.OQ +3.4% Tyson Foods Inc TSN.N +2.8% Advanced Micro Devices Inc AMD.OQ +2.7% Generac Holdings Inc GNRC.N +2.7% Bottom Performers Percent Change Walgreens Boots Alliance Inc WBA.OQ -6.4% Int
I
K
N
W
A
O
U
G
Reuters - 4 linggo ang nakaraan

Walgreens further reduces stake in Cencora

UPDATE 1-Walgreens further reduces stake in Cencora Adds details in paragraphs 2-7 Aug 1 (Reuters) - Walgreens Boots Alliance WBA.O said on Thursday it has sold shares in drug distributor Cencora COR.N for proceeds of about $1.1 billion . W algreens' ownership of Cencora has now decreased from about 12% to about 10%, it said. Walgreens has sold shares worth $818 million and Cencora has agreed to repurchase shares worth $250 million, the companies said.
W
Reuters - 4 linggo ang nakaraan

Walgreens sells shares in Cencora for about $1.1 billion

Walgreens sells shares in Cencora for about $1.1 billion Aug 1 (Reuters) - Walgreens Boots Alliance WBA.O said on Thursday it has sold shares for proceeds of about $1.1 billion in drug distributor Cencora COR.N . Reporting by Sneha S K in Bengaluru; editing by Alan Barona
W
Reuters - 1 buwan ang nakaraan

JPMorgan Sounds Out Investors On Potential Walgreens Junk Bond - Bloomberg News

BRIEF-JPMorgan Sounds Out Investors On Potential Walgreens Junk Bond - Bloomberg News July 25 (Reuters) - JPMORGAN SOUNDS OUT INVESTORS ON POTENTIAL WALGREENS JUNK BOND - BLOOMBERG NEWS Source text: https://tinyurl.com/4whtzss8 Further company coverage: JPM.N
J
W
Reuters - 1 buwan ang nakaraan

Walgreens Gets $25 Mln BARDA Award To Conduct Clinical Study On Novel Covid-19

BRIEF-Walgreens Gets $25 Mln BARDA Award To Conduct Clinical Study On Novel Covid-19 July 23 (Reuters) - Walgreens Boots Alliance Inc WBA.O : WALGREENS RECEIVES BARDA PROJECT NEXTGEN AWARD TO CONDUCT NOVEL COVID-19 DECENTRALIZED CLINICAL STUDY WALGREENS BOOTS ALLIANCE INC - RECEIVES $25M AWARD FROM BARDA Source text for Eikon: ID:nBw43bnPma Further
W
Reuters - 1 buwan ang nakaraan

Barclays lowers Walgreens PT to Street low

BUZZ-Barclays lowers Walgreens PT to Street low ** Brokerage Barclays lowers PT on Walgreens WBA.O to Street low of $7 from $11 ** New PT represents a 36.4% downside to stock's last close ** Brokerage also cuts FY25 revenue and profit forecast from $146.9 bln ​and ​$2.58 per share to $145.1 bln and ​$1.74 per share, respectively ** Says updating model "to reflect lower U.S.
W
Reuters - 1 buwan ang nakaraan

Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Cintas Corp CTAS.OQ +5.9% Warner Bros Discovery Inc WBD.OQ +3.4% Meta Platforms Inc META.OQ +3.2% Broadcom Inc AVGO.OQ +2.5% NVIDIA Corp NVDA.OQ +2.3% Bottom Performers Percent Change MongoDB Inc MDB.OQ -5.2% IDEXX Laboratories Inc IDXX.OQ -5.1% Cadence Design Systems Inc CDNS.OQ -4.2% Walgreens Boots Alliance Inc WBA.OQ -4.0% CrowdStrike Holdings Inc CRWD.OQ -3.6% The Nasdaq 100
B
C
C
I
N
W
U
C
Reuters - 2 buwan ang nakaraan

US FDA declines to approve Orexo's opioid overdose drug

UPDATE 2-US FDA declines to approve Orexo's opioid overdose drug Adds details from paragraph 3 onward July 16 (Reuters) - The U.S. Food and Drug Administration (FDA) has declined to approve Orexo AB's ORX.ST high-dose prescription drug for opioid overdose, the company said on Tuesday. The health regulator, in a so-called complete response letter, has sought an additional Human Factors (HF) study and additional technical data on the final commercial product, the company said.
W
Reuters - 2 buwan ang nakaraan

Super Micro rises as set to join Nasdaq 100 index

BUZZ-Super Micro rises as set to join Nasdaq 100 index ** Super Micro Computer's SMCI.O shares up 3.5% at $941.53 premarket ahead of its Nasdaq 100 inclusion next week ** AI-optimized server maker to replace Walgreens Boots Alliance WBA.O in Nasdaq-100 Index .NDX and Nasdaq-100 Equal Weighted Index .NDXE effective Mon, Jul 22, the Nasdaq .NDAQ said late Fri ** NDX index comprises 100 of the largest of world's non-financial cos on the Nasdaq stock market based on market cap ** Super Micro will be
W
U

Kundisyon

Mga Patok na Assets

Disclaimer: Ang mga kabilang sa XM Group ay nagbibigay lang ng serbisyo sa pagpapatupad at pag-access sa aming Online Trading Facility, kung saan pinapahintulutan nito ang pagtingin at/o paggamit sa nilalaman na makikita sa website o sa pamamagitan nito, at walang layuning palitan o palawigin ito, at hindi din ito papalitan o papalawigin. Ang naturang pag-access at paggamit ay palaging alinsunod sa: (i) Mga Tuntunin at Kundisyon; (ii) Mga Babala sa Risk; at (iii) Kabuuang Disclaimer. Kaya naman ang naturang nilalaman ay ituturing na pangkalahatang impormasyon lamang. Mangyaring isaalang-alang na ang mga nilalaman ng aming Online Trading Facility ay hindi paglikom, o alok, para magsagawa ng anumang transaksyon sa mga pinansyal na market. Ang pag-trade sa alinmang pinansyal na market ay nagtataglay ng mataas na lebel ng risk sa iyong kapital.

Lahat ng materyales na nakalathala sa aming Online Trading Facility ay nakalaan para sa layuning edukasyonal/pang-impormasyon lamang at hindi naglalaman – at hindi dapat ituring bilang naglalaman – ng payo at rekomendasyon na pangpinansyal, tungkol sa buwis sa pag-i-invest, o pang-trade, o tala ng aming presyo sa pag-trade, o alok para sa, o paglikom ng, transaksyon sa alinmang pinansyal na instrument o hindi ginustong pinansyal na promosyon.

Sa anumang nilalaman na galing sa ikatlong partido, pati na ang mga nilalaman na inihanda ng XM, ang mga naturang opinyon, balita, pananaliksik, pag-analisa, presyo, ibang impormasyon o link sa ibang mga site na makikita sa website na ito ay ibibigay tulad ng nandoon, bilang pangkalahatang komentaryo sa market at hindi ito nagtataglay ng payo sa pag-i-invest. Kung ang alinmang nilalaman nito ay itinuring bilang pananaliksik sa pag-i-invest, kailangan mong isaalang-alang at tanggapin na hindi ito inilaan at inihanda alinsunod sa mga legal na pangangailangan na idinisenyo para maisulong ang pagsasarili ng pananaliksik sa pag-i-invest, at dahil dito ituturing ito na komunikasyon sa marketing sa ilalim ng mga kaugnay na batas at regulasyon. Mangyaring siguruhin na nabasa at naintindihan mo ang aming Notipikasyon sa Hindi Independyenteng Pananaliksik sa Pag-i-invest at Babala sa Risk na may kinalaman sa impormasyong nakalagay sa itaas, na maa-access dito.

Babala sa Risk: Maaaring malugi ang iyong kapital. Maaaring hindi nababagay sa lahat ang mga produktong naka-leverage. Mangyaring isaalang-alang ang aming Pahayag sa Risk.